Dramatic Improvement in NHL Outcomes With CAR T-Cell Versus Standard Therapy – OncLive
OncLive |
Dramatic Improvement in NHL Outcomes With CAR T-Cell Versus Standard Therapy
OncLive Treatment with the autologous anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (axi-cel) significantly improved outcomes in refractory non-Hodgkin lymphoma (NHL) compared with standard therapies, a standardized analyses of 2 clinical trials showed. |
